Balancing Cost and Access to Quality Care for Therapeutic Advancements in Psoriasis

• Release Date: February 1, 2024
• Expiration Date: July 31, 2025
• Estimated Time to Complete Activity: 0.75 hours
• Compatible with all modern browsers and mobile devices

Expert Faculty Presenters:

Jason Harris Vice President of Government Relations & Advocacy National Psoriasis Foundation Click here for biography James Kenney, RPh, MBA President JTKENNEY, LLC Click here for biography Heather Woolery-Lloyd, MD, FAAD Director, Skin of Color Division Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Johns Hopkins School of Medicine Click here for biography

Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.

Statement of Need/Program Overview
Psoriasis is a complex disease and appropriate management is correspondingly challenging. Lack of access to appropriate treatment can result in patients postponing or forgoing care, leading to treatment delays and disease progression, both of which can contribute to increased morbidity and higher costs. Recently two novel topicals were approved for once-daily treatment of patients with mild, moderate, and severe plaque psoriasis. Despite the rapidly increasing number of therapeutic options for patients with psoriasis, there remain several unanswered questions regarding how to appropriately match specific agents to individual patients.

Educational Objectives
After completing this activity, the participant should be better able to:

• Assess how emerging and recently approved psoriasis therapies impact disease control and fit into the treatment algorithm.
• Recognize comorbidities, history, and patient preferences that influence therapeutic selection.
• Employ timely referral and collaborative, multidisciplinary management for all patients with psoriasis.
• Apply strategies to improve and expedite access to high quality psoriasis care and treatment.

Accreditation Information

Joint Accreditation Statement This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
PACE designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 0.75 contact hour (0.75 CEU) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-020-H01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour.

Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The PACE planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.